AI Tokens
Stock Analysis on Net

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Turnover Ratios

Average No. Days

Johnson & Johnson, short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Turnover Ratios
Inventory turnover 2.10 2.08 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Receivables turnover 5.23 5.14 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Payables turnover 3.46 3.41 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Working capital turnover 111.11 20.07 66.14 62.88 24.63 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 — 4.88 5.02 5.57
Average No. Days
Average inventory processing period 174 176 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Add: Average receivable collection period 70 71 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Operating cycle 244 247 239 238 246 240 228 226 236 233 222 218 211 232 220 209 196 198 192
Less: Average payables payment period 106 107 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Cash conversion cycle 138 140 116 93 127 121 105 89 116 112 109 86 100 99 100 72 78 82 80

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


An analysis of the short-term activity ratios indicates a general decline in operational efficiency over the observed period. The most prominent trend is the steady elongation of the cash conversion cycle, which increased from 80 days in early 2022 to 138 days by late 2026, signaling that more capital is tied up in operating activities for longer durations.

Inventory Management
A consistent downward trend is observed in inventory turnover, which decreased from 2.77 to 2.10. This correlate with a significant increase in the average inventory processing period, rising from 132 days to 174 days. These metrics suggest a slowing rate of inventory movement and an increase in the time required to convert raw materials and finished goods into sales.
Receivables Management
Receivables turnover experienced a gradual decline from 6.08 to 5.23. Consequently, the average receivable collection period extended from 60 days to 70 days. While the decline is less aggressive than that of inventory, it reflects a slowing efficiency in collecting payments from customers.
Payables Management
Payables turnover remained relatively volatile, fluctuating between a high of 3.46 and a low of 2.52. The average payables payment period showed no linear trend, peaking at 145 days in December 2025 before settling at 106 days by September 2026. The lack of a corresponding increase in payment periods failed to offset the slowing inventory and receivable cycles.
Operational Cycles and Working Capital
The operating cycle expanded from 192 days to 244 days, driven primarily by the combined slowdown in inventory processing and receivable collections. Working capital turnover exhibited extreme volatility, particularly from 2024 onward, with significant spikes reaching 284.99 in June 2025 and 111.11 in September 2026. This high variance suggests substantial fluctuations in the relationship between net working capital and net sales, potentially indicating periods of very low or negative working capital.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Inventory Turnover

Johnson & Johnson, inventory turnover calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Cost of products sold 8,097 8,051 8,106 7,968 7,303 7,628 7,357 7,128 6,963 6,869 6,511 6,798 6,606 6,462 6,687 7,765 7,807 7,919 7,598
Inventories 15,377 15,144 14,583 14,191 14,146 13,412 12,659 12,444 12,603 12,169 11,383 11,181 11,198 12,888 12,809 12,483 11,675 11,437 10,990
Short-term Activity Ratio
Inventory turnover1 2.10 2.08 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. — 3.58 3.65 3.68 3.65 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96
Amgen Inc. — 1.87 1.91 1.93 1.92 1.88 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48
Bristol-Myers Squibb Co. — 5.36 5.20 5.18 5.31 5.18 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55
Danaher Corp. 3.38 3.20 3.90 4.04 3.67 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87
Eli Lilly & Co. — 0.79 0.85 0.80 0.83 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93
Gilead Sciences Inc. — 3.18 3.21 3.51 3.47 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50
Merck & Co. Inc. — 2.90 2.65 2.46 2.27 2.25 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74
Pfizer Inc. — 1.72 1.57 1.51 1.46 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67
Regeneron Pharmaceuticals Inc. — 0.76 0.74 0.66 0.64 0.64 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27
Thermo Fisher Scientific Inc. — 4.87 4.87 4.85 4.47 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87
Vertex Pharmaceuticals Inc. — 1.00 0.95 0.98 0.99 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Inventory turnover = (Cost of products soldQ3 2026 + Cost of products soldQ2 2026 + Cost of products soldQ1 2026 + Cost of products soldQ4 2025) ÷ Inventories
= (8,097 + 8,051 + 8,106 + 7,968) ÷ 15,377 = 2.10

2 Click competitor name to see calculations.


An overall downward trajectory in inventory efficiency is evident throughout the analyzed period. The inventory turnover ratio declined from 2.77 in April 2022 to 2.10 by September 2026, indicating a prolonged cycle for converting inventory into sales.

Inventory Turnover Analysis
The ratio experienced a consistent decline from the initial peak of 2.77 in early 2022. While a brief recovery occurred in October 2023, where the ratio rose to 2.46, the metric generally trended lower, reaching a minimum of 2.08 in June 2026. This suggests a decrease in the velocity of inventory movement over the four-year span.
Cost of Products Sold (COPS) Trends
COPS exhibited fluctuations, starting at 7,598 million USD in April 2022 and dipping to a period low of 6,462 million USD in July 2023. Following this trough, a steady growth trend emerged, with costs increasing to a peak of 8,106 million USD by March 2026 before stabilizing around 8,097 million USD by the end of the period.
Inventory Asset Growth
Inventory levels showed a substantial long-term increase, rising from 10,990 million USD in April 2022 to 15,377 million USD by September 2026. Despite a temporary reduction in late 2023—where levels dropped to approximately 11,181 million USD—the subsequent growth in inventory volume significantly outpaced the growth in the cost of products sold.
Operational Efficiency Insights
The contraction of the turnover ratio is primarily driven by the disproportionate increase in inventory holdings relative to the cost of goods sold. The rise in inventory from approximately 11 billion USD to over 15 billion USD, while COPS grew more modestly from 7.6 billion USD to 8.1 billion USD, confirms a decline in operational efficiency regarding stock management.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Receivables Turnover

Johnson & Johnson, receivables turnover calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Sales to customers 25,399 25,310 24,062 24,564 23,993 23,743 21,893 22,520 22,471 22,447 21,383 21,395 21,351 21,519 20,894 23,706 23,791 24,020 23,426
Accounts receivable, trade, less allowances 18,987 19,046 17,721 17,178 17,611 17,846 16,020 14,842 16,174 15,794 14,946 14,873 14,798 16,777 16,350 16,160 15,890 16,139 15,594
Short-term Activity Ratio
Receivables turnover1 5.23 5.14 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. — 4.66 5.03 4.86 4.67 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29
Amgen Inc. — 3.55 3.88 3.67 4.06 3.85 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81
Danaher Corp. 6.21 6.33 6.49 6.28 6.46 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87
Eli Lilly & Co. — 3.97 3.92 3.67 3.69 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64
Gilead Sciences Inc. — 5.90 6.17 5.89 5.60 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18
Merck & Co. Inc. — 5.30 5.39 5.52 5.30 5.37 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49
Pfizer Inc. — 5.10 5.03 5.27 4.40 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99
Regeneron Pharmaceuticals Inc. — 2.37 2.60 2.50 2.51 2.53 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41
Thermo Fisher Scientific Inc. — 4.90 4.91 5.01 4.91 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21
Vertex Pharmaceuticals Inc. — 5.90 6.12 5.85 6.02 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Receivables turnover = (Sales to customersQ3 2026 + Sales to customersQ2 2026 + Sales to customersQ1 2026 + Sales to customersQ4 2025) ÷ Accounts receivable, trade, less allowances
= (25,399 + 25,310 + 24,062 + 24,564) ÷ 18,987 = 5.23

2 Click competitor name to see calculations.


The analysis of receivables turnover indicates a gradual decline in the efficiency of credit collection over the period from April 2022 to September 2026.

Long-term Turnover Trend
The receivables turnover ratio exhibits a downward trajectory, moving from a peak of 6.08 in April 2022 to 5.23 by September 2026. This overall decrease suggests that the company is taking longer to collect its trade receivables relative to its sales volume.
Correlation Between Revenue and Receivables
Sales to customers demonstrated a recovery and subsequent growth phase, rising from approximately 20.9 billion in April 2023 to a high of 25.4 billion by September 2026. However, the growth in accounts receivable grew disproportionately, increasing from 15.6 billion in early 2022 to 19.0 billion by September 2026. The fact that receivables increased at a faster pace than sales contributed to the compression of the turnover ratio.
Phase-Specific Observations
The ratio remained relatively stable throughout 2022, fluctuating between 5.88 and 6.08. A period of increased volatility was observed between April 2023 and December 2024, with a notable dip to 5.36 in July 2023 followed by a temporary recovery to 5.98 in December 2024. The lowest efficiency level was reached in June 2025, where the ratio fell to 5.08, before stabilizing in the 5.14 to 5.23 range through the remainder of the observed period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Payables Turnover

Johnson & Johnson, payables turnover calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Cost of products sold 8,097 8,051 8,106 7,968 7,303 7,628 7,357 7,128 6,963 6,869 6,511 6,798 6,606 6,462 6,687 7,765 7,807 7,919 7,598
Accounts payable 9,317 9,223 10,460 11,991 9,625 9,464 9,545 10,311 8,954 8,848 8,174 9,632 8,355 10,443 9,909 11,703 10,153 9,765 9,309
Short-term Activity Ratio
Payables turnover1 3.46 3.41 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. — 4.05 4.02 5.09 4.29 4.12 5.25 6.74 5.99 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65
Bristol-Myers Squibb Co. — 3.53 3.38 3.90 3.42 2.61 3.52 3.88 3.43 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25
Danaher Corp. 6.09 5.72 5.68 5.45 5.78 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04
Eli Lilly & Co. — 2.16 2.47 2.05 2.37 2.27 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24
Gilead Sciences Inc. — 9.22 9.52 8.72 7.66 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43
Merck & Co. Inc. — 4.70 4.44 3.72 3.53 3.82 3.98 3.72 4.26 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25
Pfizer Inc. — 3.73 3.72 3.07 3.32 3.44 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66
Regeneron Pharmaceuticals Inc. — 2.03 2.24 2.24 2.30 2.83 2.84 2.50 3.87 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39
Thermo Fisher Scientific Inc. — 8.39 8.00 7.27 8.23 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96
Vertex Pharmaceuticals Inc. — 4.10 3.44 3.58 3.83 3.59 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Payables turnover = (Cost of products soldQ3 2026 + Cost of products soldQ2 2026 + Cost of products soldQ1 2026 + Cost of products soldQ4 2025) ÷ Accounts payable
= (8,097 + 8,051 + 8,106 + 7,968) ÷ 9,317 = 3.46

2 Click competitor name to see calculations.


The analysis of payables turnover reveals a period of moderate volatility characterized by cyclical fluctuations, with the ratio generally oscillating between a low of 2.52 and a high of 3.46. There is a observable inverse relationship between the volume of accounts payable and the turnover ratio, where spikes in outstanding payables consistently correspond with declines in the turnover rate.

Payables Turnover Trends
The ratio experienced notable dips during the final quarters of 2022 and 2025, reaching 2.66 and 2.52 respectively. These troughs align with peaks in accounts payable, suggesting periods of extended payment terms or increased procurement volumes at year-end. Conversely, the ratio reached its highest levels toward the end of the observed period, peaking at 3.46 in September 2026, indicating an acceleration in the rate at which supplier obligations are settled.
Cost of Products Sold Dynamics
Cost of products sold exhibited a downward shift in early 2023, dropping from approximately 7.8 billion to 6.5 billion. Following this period, a sustained upward trajectory was observed, with costs rising steadily to exceed 8 billion by early 2026. This growth in expenditure provided the baseline for the turnover calculations and reflects increasing operational costs over the latter half of the period.
Accounts Payable Management
Accounts payable demonstrated significant variance, fluctuating between 8.17 billion in March 2024 and 11.99 billion in December 2025. The volatility in this balance suggests a non-linear payment schedule. A notable contraction in payables occurred throughout 2024, which contributed to a temporary stabilization of the turnover ratio before a significant spike in payables occurred at the end of 2025.
Recent Performance Analysis
A distinct upward trend in efficiency is evident in the final three quarters of the dataset. From March 2026 to September 2026, the payables turnover increased from 2.96 to 3.46. This trend coincided with a decrease in accounts payable despite rising costs of products sold, signifying a strategic shift toward faster supplier payments or a reduction in reliance on trade credit.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Working Capital Turnover

Johnson & Johnson, working capital turnover calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Current assets 56,351 59,774 59,173 55,624 54,611 54,498 71,551 55,893 53,249 57,817 57,002 53,495 53,703 60,567 64,388 55,294 65,236 63,847 60,424
Less: Current liabilities 55,457 54,895 57,716 54,126 50,869 54,180 56,903 50,321 51,759 53,933 48,725 46,282 44,370 54,170 60,373 55,802 45,543 44,821 43,390
Working capital 894 4,879 1,457 1,498 3,742 318 14,648 5,572 1,490 3,884 8,277 7,213 9,333 6,397 4,015 (508) 19,693 19,026 17,034
 
Sales to customers 25,399 25,310 24,062 24,564 23,993 23,743 21,893 22,520 22,471 22,447 21,383 21,395 21,351 21,519 20,894 23,706 23,791 24,020 23,426
Short-term Activity Ratio
Working capital turnover1 111.11 20.07 66.14 62.88 24.63 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 — 4.88 5.02 5.57
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc. — — — — — — — — — — — — — — — — — — —
Amgen Inc. — 3.83 5.44 9.85 5.66 5.35 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34
Bristol-Myers Squibb Co. — 4.81 5.84 7.83 6.20 8.09 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24
Danaher Corp. 4.46 4.76 3.83 4.13 7.39 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91
Eli Lilly & Co. — 4.71 3.97 3.19 2.71 4.92 4.38 10.32 6.06 12.62 5.45 — 31.79 12.21 5.77 31.84 14.71 19.45 8.19
Gilead Sciences Inc. — 10.20 3.19 4.43 5.12 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68
Merck & Co. Inc. — 7.44 8.15 4.28 3.39 5.77 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09
Pfizer Inc. — 7.31 7.47 10.58 6.08 10.68 6.64 8.64 5,036.00 — 29.17 — 1.62 2.03 6.89 11.00 3.83 5.05 6.10
Regeneron Pharmaceuticals Inc. — 1.20 1.14 1.05 1.05 1.08 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46
Thermo Fisher Scientific Inc. — 5.59 5.87 3.30 5.90 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13
Vertex Pharmaceuticals Inc. — 1.46 1.56 1.64 1.92 1.82 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Working capital turnover = (Sales to customersQ3 2026 + Sales to customersQ2 2026 + Sales to customersQ1 2026 + Sales to customersQ4 2025) ÷ Working capital
= (25,399 + 25,310 + 24,062 + 24,564) ÷ 894 = 111.11

2 Click competitor name to see calculations.


The working capital turnover ratio exhibits significant volatility throughout the analyzed period, primarily driven by substantial fluctuations in the underlying working capital rather than shifts in sales revenue. While sales to customers remained relatively stable with a gradual upward trend, the ratio experienced extreme peaks and troughs, indicating inconsistent levels of net current assets relative to operational output.

Revenue Stability and Growth
Sales to customers showed resilience and moderate growth, fluctuating between a low of 20,894 million US$ in April 2023 and a peak of 25,399 million US$ by September 2026. This stability suggests that the dramatic swings in the turnover ratio are not the result of revenue instability but are instead linked to changes in the balance sheet components of working capital.
Working Capital Volatility
Working capital displayed extreme variance, moving from a high of 19,693 million US$ in October 2022 to a negative value of -508 million US$ by December 2022. Similar sharp contractions occurred in June 2025 (318 million US$) and September 2026 (894 million US$). These rapid decreases in working capital significantly inflate the turnover ratio, as a smaller asset base is used to support a consistent level of sales.
Working Capital Turnover Ratio Trends
The turnover ratio began at a relatively stable range of 4.88 to 5.57 in 2022. However, subsequent periods saw a marked increase in volatility. Notable peaks occurred in September 2024 (58.86), June 2025 (284.99), and September 2026 (111.11). These spikes correspond directly with periods where working capital reached its lowest positive levels, suggesting an aggressive reduction in net current assets or significant shifts in short-term liability management.
Operational Efficiency Insights
The progression from lower ratios in 2022 to extremely high ratios in 2025 and 2026 indicates a trend toward operating with significantly leaner working capital. While higher turnover ratios typically suggest greater efficiency in using short-term assets to generate sales, the extreme magnitude of the peaks suggests potential instability or strategic restructuring of current assets and liabilities rather than a linear improvement in operational efficiency.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Average Inventory Processing Period

Johnson & Johnson, average inventory processing period calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Inventory turnover 2.10 2.08 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Short-term Activity Ratio (no. days)
Average inventory processing period1 174 176 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. — 102 100 99 100 107 98 90 89 75 75 73 77 85 81 75 66 73 74
Amgen Inc. — 195 191 189 190 194 195 199 209 257 321 411 259 265 279 281 272 260 247
Bristol-Myers Squibb Co. — 68 70 70 69 70 69 67 102 98 99 91 84 83 93 84 76 79 80
Danaher Corp. 108 114 94 90 99 101 96 88 101 102 98 96 104 102 104 91 96 98 94
Eli Lilly & Co. — 463 428 454 441 435 379 329 349 316 312 298 261 267 268 237 196 204 189
Gilead Sciences Inc. — 115 114 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Merck & Co. Inc. — 126 138 148 160 162 150 147 149 153 151 144 139 137 134 124 118 119 133
Pfizer Inc. — 212 232 242 251 239 229 222 219 178 170 149 138 158 119 95 101 100 99
Regeneron Pharmaceuticals Inc. — 479 491 556 571 570 582 572 573 562 553 519 508 532 549 562 440 379 287
Thermo Fisher Scientific Inc. — 75 75 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Vertex Pharmaceuticals Inc. — 365 384 373 369 345 320 287 267 238 222 214 213 192 177 156 136 135 129

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.10 = 174

2 Click competitor name to see calculations.


An analysis of the short-term operating activity ratios reveals a consistent decline in inventory management efficiency from April 2022 through September 2026. A clear inverse correlation is observed between the inventory turnover ratio and the average inventory processing period, indicating a slowing rate of inventory conversion into sales.

Inventory Turnover Analysis
The inventory turnover ratio exhibits a steady downward trajectory, falling from a high of 2.77 in April 2022 to 2.10 by September 2026. The most significant erosion of this ratio occurred between April 2022 and July 2023, during which the value dropped to 2.23. Following this period, the ratio stabilized, fluctuating within a tight range between 2.08 and 2.24 from March 2024 through the end of the analyzed period.
Average Inventory Processing Period Analysis
The average inventory processing period shows a corresponding upward trend, extending from 132 days in April 2022 to 174 days in September 2026. A sharp increase is noted in the first year, reaching 164 days by July 2023. While a temporary contraction to 149 days occurred in October 2023, the period generally continued to expand, reaching peaks of 176 days in September 2025 and June 2026.

The overall trend indicates a degradation in operational efficiency regarding inventory throughput. The expansion of the processing period by approximately 42 days over the observed timeframe suggests that capital is tied up in inventory for longer durations, which may point to shifts in demand patterns or changes in supply chain management strategies.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Average Receivable Collection Period

Johnson & Johnson, average receivable collection period calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Receivables turnover 5.23 5.14 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Short-term Activity Ratio (no. days)
Average receivable collection period1 70 71 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. — 78 73 75 78 79 79 71 75 78 80 75 76 75 74 71 68 72 69
Amgen Inc. — 103 94 99 90 95 91 77 86 86 88 99 88 84 84 82 79 79 76
Danaher Corp. 59 58 56 58 56 54 54 54 54 51 52 60 59 55 53 57 51 54 53
Eli Lilly & Co. — 92 93 99 99 97 90 89 92 103 80 97 93 93 99 88 84 80 79
Gilead Sciences Inc. — 62 59 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Merck & Co. Inc. — 69 68 66 69 68 62 58 66 68 68 63 64 69 66 58 59 62 66
Pfizer Inc. — 72 73 69 83 69 69 66 87 74 72 69 58 48 48 40 59 55 52
Regeneron Pharmaceuticals Inc. — 154 140 146 146 144 144 160 161 155 146 158 156 148 151 160 148 132 107
Thermo Fisher Scientific Inc. — 74 74 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Vertex Pharmaceuticals Inc. — 62 60 62 61 61 59 53 60 58 64 58 58 60 61 59 58 58 59

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.23 = 70

2 Click competitor name to see calculations.


Analysis of short-term operating activity indicates a gradual decline in the efficiency of receivables management over the period from April 2022 through September 2026.

Receivables Turnover
The turnover ratio exhibits a general downward trajectory, beginning at 6.08 in April 2022 and concluding at 5.23 in September 2026. Although periodic fluctuations occurred—most notably a temporary recovery to 5.98 in December 2024—the long-term trend is negative. The ratio reached its lowest point in June 2025 at 5.08, reflecting a decreased frequency in the conversion of receivables into cash.
Average Receivable Collection Period
The collection period has lengthened over the observed timeframe, rising from 60 days in early 2022 to 70 days by September 2026. A peak of 72 days was recorded in June 2025, coinciding with the lowest turnover ratio. This expansion in the number of days required to collect payments suggests a reduction in the velocity of cash inflows from credit sales.

The inverse correlation between the declining turnover ratio and the increasing collection period indicates a systemic slowing of the credit-to-cash cycle. This trend suggests that a larger portion of working capital is being tied up in accounts receivable, which may influence short-term liquidity and necessitate a review of credit terms or collection strategies.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Operating Cycle

Johnson & Johnson, operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Average inventory processing period 174 176 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Average receivable collection period 70 71 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Short-term Activity Ratio
Operating cycle1 244 247 239 238 246 240 228 226 236 233 222 218 211 232 220 209 196 198 192
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. — 180 173 174 178 186 177 161 164 153 155 148 153 160 155 146 134 145 143
Amgen Inc. — 298 285 288 280 289 286 276 295 343 409 510 347 349 363 363 351 339 323
Danaher Corp. 167 172 150 148 155 155 150 142 155 153 150 156 163 157 157 148 147 152 147
Eli Lilly & Co. — 555 521 553 540 532 469 418 441 419 392 395 354 360 367 325 280 284 268
Gilead Sciences Inc. — 177 173 166 170 169 159 156 160 172 164 163 169 163 159 162 137 136 132
Merck & Co. Inc. — 195 206 214 229 230 212 205 215 221 219 207 203 206 200 182 177 181 199
Pfizer Inc. — 284 305 311 334 308 298 288 306 252 242 218 196 206 167 135 160 155 151
Regeneron Pharmaceuticals Inc. — 633 631 702 717 714 726 732 734 717 699 677 664 680 700 722 588 511 394
Thermo Fisher Scientific Inc. — 149 149 148 156 153 148 142 150 144 142 142 146 146 145 145 148 157 164
Vertex Pharmaceuticals Inc. — 427 444 435 430 406 379 340 327 296 286 272 271 252 238 215 194 193 188

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 174 + 70 = 244

2 Click competitor name to see calculations.


An overall expansion of the operating cycle is evident throughout the analyzed period, shifting from 192 days in April 2022 to 244 days by September 2026. This trend indicates a systemic slowdown in the duration required to convert operational inputs into cash.

Average Inventory Processing Period
This metric serves as the primary driver of the overall cycle expansion. The period grew from 132 days in April 2022 to a peak of 176 days in June 2026, ending the period at 174 days. The sustained increase suggests a decrease in inventory turnover efficiency or a strategic shift toward maintaining higher inventory levels.
Average Receivable Collection Period
A moderate upward trend is observed in the time required to collect receivables, which increased from 60 days in April 2022 to 70 days by September 2026. Although this metric remains more stable than the inventory processing period, the general increase suggests a slight decline in collection efficiency or a modification in credit terms offered to customers.
Operating Cycle Dynamics
The cumulative effect of the increasing inventory and receivable periods has resulted in a total cycle expansion of 52 days over the timeframe. While temporary contractions occurred—most notably in October 2023 and December 2024—the overarching trajectory remains positive, indicating a growing requirement for working capital to support the operational loop.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Average Payables Payment Period

Johnson & Johnson, average payables payment period calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Payables turnover 3.46 3.41 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Short-term Activity Ratio (no. days)
Average payables payment period1 106 107 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. — 90 91 72 85 89 70 54 61 73 60 69 70 64 73 90 69 72 78
Bristol-Myers Squibb Co. — 103 108 94 107 140 104 94 106 120 117 111 97 108 114 109 96 107 112
Danaher Corp. 60 64 64 67 63 65 66 66 60 63 62 65 65 63 64 67 65 73 72
Eli Lilly & Co. — 169 148 178 154 161 140 140 135 142 127 134 130 138 119 106 86 87 70
Gilead Sciences Inc. — 40 38 42 48 34 43 49 49 29 34 31 37 40 41 58 33 31 32
Merck & Co. Inc. — 78 82 98 103 95 92 98 86 83 81 89 80 80 84 89 71 75 86
Pfizer Inc. — 98 98 119 110 106 110 115 99 79 87 98 72 93 76 72 66 59 55
Regeneron Pharmaceuticals Inc. — 180 163 163 158 129 129 146 94 110 137 122 106 116 136 138 98 91 68
Thermo Fisher Scientific Inc. — 43 46 50 44 43 44 45 38 37 37 41 35 34 39 48 37 41 46
Vertex Pharmaceuticals Inc. — 89 106 102 95 102 105 98 98 85 96 106 117 115 107 103 44 73 66

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 3.46 = 106

2 Click competitor name to see calculations.


The analysis of operating activity ratios reveals a cyclical pattern in the management of accounts payable, characterized by consistent seasonal fluctuations in both the payables turnover ratio and the average payables payment period.

Seasonal Payment Patterns
A recurring trend is observed where the average payables payment period extends significantly during the fourth quarter of each year. Peaks were recorded in December 2022 (137 days), December 2024 (137 days), and reached a maximum in December 2025 (145 days). This suggests a systematic deferral of supplier payments toward the end of the calendar year.
Payables Turnover Dynamics
The payables turnover ratio exhibits a direct inverse relationship with the payment period. Troughs in turnover typically coincide with year-end payment extensions, with the lowest ratio of 2.52 occurring in December 2025. Conversely, turnover efficiency increased during the second and third quarters of 2026, reaching a peak of 3.46 by September 27, 2026.
Recent Trend Observations
Following the peak extension in December 2025, a notable contraction in the payment cycle is evident throughout 2026. The average payment period decreased from 123 days in March 2026 to 106 days by September 2026, representing the lowest payment duration across the entire analyzed timeframe.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Cash Conversion Cycle

Johnson & Johnson, cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Average inventory processing period 174 176 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Average receivable collection period 70 71 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Average payables payment period 106 107 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Short-term Activity Ratio
Cash conversion cycle1 138 140 116 93 127 121 105 89 116 112 109 86 100 99 100 72 78 82 80
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc. — 208 194 216 195 200 216 222 234 270 349 441 277 285 290 273 282 267 245
Danaher Corp. 107 108 86 81 92 90 84 76 95 90 88 91 98 94 93 81 82 79 75
Eli Lilly & Co. — 386 373 375 386 371 329 278 306 277 265 261 224 222 248 219 194 197 198
Gilead Sciences Inc. — 137 135 124 122 135 116 107 111 143 130 132 132 123 118 104 104 105 100
Merck & Co. Inc. — 117 124 116 126 135 120 107 129 138 138 118 123 126 116 93 106 106 113
Pfizer Inc. — 186 207 192 224 202 188 173 207 173 155 120 124 113 91 63 94 96 96
Regeneron Pharmaceuticals Inc. — 453 468 539 559 585 597 586 640 607 562 555 558 564 564 584 490 420 326
Thermo Fisher Scientific Inc. — 106 103 98 112 110 104 97 112 107 105 101 111 112 106 97 111 116 118
Vertex Pharmaceuticals Inc. — 338 338 333 335 304 274 242 229 211 190 166 154 137 131 112 150 120 122

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 174 + 70 – 106 = 138

2 Click competitor name to see calculations.


The cash conversion cycle exhibits a significant upward trend over the analyzed period, indicating a lengthening of the time required to convert resource inputs into cash flows. The cycle began at 80 days in April 2022 and expanded to 138 days by September 2026, representing a substantial decrease in operational liquidity efficiency.

Average Inventory Processing Period
A consistent and pronounced increase is observed in the time required to process inventory. Starting at 132 days in April 2022, the period climbed steadily to a peak of 176 days in June 2026, ending the period at 174 days. This upward trajectory suggests a slowing of inventory turnover, which serves as the primary driver for the overall extension of the cash conversion cycle.
Average Receivable Collection Period
The collection of receivables remained relatively stable but showed a slight overall increase. The period fluctuated between a low of 60 days in 2022 and a peak of 72 days in June 2023. By September 2026, the period stood at 70 days, indicating a marginal slowing in the speed at which credit sales are converted into cash.
Average Payables Payment Period
The payables payment period demonstrates high volatility. It peaked at 145 days in December 2025, suggesting a period of extended credit utilization from suppliers. However, a sharp decline followed, dropping to 106 days by September 2026. This recent compression in the payment period reduces the company's ability to offset the costs of inventory and receivables, further accelerating the increase in the total cash conversion cycle.

The deterioration of the cash conversion cycle is the result of a compounding effect between rising inventory holding times and a recent reduction in the payables payment period. While the receivable collection period remained largely contained, the inability to maintain high payables durations in the latter part of the period, coupled with systemic inventory slowing, has led to a higher requirement for working capital to support operations.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?